The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics

Inherited genetic variations in pharmacogenetic loci are widely acknowledged as important determinants of phenotypic differences in drug response, and may be actionable in the clinic. However, recent studies suggest that a considerable number of novel rare variants in pharmacogenes likely contribute...

Full description

Saved in:
Bibliographic Details
Published in:Cold Spring Harbor perspectives in medicine 2019-02, Vol.9 (2), p.a033027
Main Authors: Schwarz, Ute I, Gulilat, Markus, Kim, Richard B
Format: Article
Language:English
Subjects:
Computational Biology
Genetic Variation
High-Throughput Nucleotide Sequencing - methods
High-Throughput Screening Assays
Humans
Pharmacogenetics - methods
Phenotype
Sequence Analysis, DNA - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inherited genetic variations in pharmacogenetic loci are widely acknowledged as important determinants of phenotypic differences in drug response, and may be actionable in the clinic. However, recent studies suggest that a considerable number of novel rare variants in pharmacogenes likely contribute to a still unexplained fraction of the observed interindividual variability. Next-generation sequencing (NGS) represents a rapid, relatively inexpensive, large-scale DNA sequencing technology with potential relevance as a comprehensive pharmacogenetic genotyping platform to identify genetic variation related to drug therapy. However, many obstacles remain before the clinical use of NGS-based test results, including technical challenges, functional interpretation, and strict requirements for diagnostic tests. Advanced computational analyses, high-throughput screening methodologies, and generation of shared resources with cell-based and clinical information will facilitate the integration of NGS data into candidate genotyping approaches, likely enhancing future drug phenotype predictions in patients.
ISSN:2157-1422
2472-5412
DOI:10.1101/cshperspect.a033027